To create prescriptive size charts of six clinically relevant fetal brain structures measured by ultrasound. Methods: INTERGROWTH-21st is a multicentre population-based project, conducted between 2009 and 2014 in eight countries. The primary aim was to study growth, health, nutrition and neurodevelopment from intrauterine life (<14+0 weeks of gestation) to infancy. Ensuring equal distribution across gestational age and country of origin, stored 3D ultrasound data from a subgroup of women taking part were randomly selected, based on a sample size calculation. The parieto-occipital fissure, sylvian fissure, anterior ventricle, posterior ventricle, transcerebellar diameter and cisterna magna were measured on reconstructed axial planes. Follow-up motor assessment at age 1 year was considered normal if achievement of milestones was within the expected for age as defined by the WHO. Results: A total of 442 volumes from singleton pregnancies resulting in livebirths without congenital malformations were included. Women were confirmed to be at low risk of obstetric complications: pre-eclampsia, preterm labour before 37 weeks, term low birth weight, preterm premature rupture of membranes, neonatal special care admission and neonatal mortality were <1%, 4.9%, 2.2%, 1.35%, <1% and <1%, respectively. Motor assessment, available in 297 children, was normal in 98% of the participants. All measured structures increased in size with advancing gestation; in all, except the anterior ventricle, there was an increase in variability with advancing gestation. The best fitting powers were provided by second-degree fractional polynomials. Differences between the observed and smoothed centiles for the 3rd, 50th, and 97th centiles 16-19 September 2017, Vienna, Austria Oral communication abstracts were small for both mean (range 0.0-0.5mm) and standard deviation (range 0.0-2.6mm). Conclusions: Prescriptive size charts for the development of the fetal brain were created from fetuses at low risk of abnormal development. We recommend these charts as international standards for measurements by ultrasound.
cases reported were diagnosed postnatally, with few cases diagnosed prenatally.
We report four fetuses from two unrelated families with RNU4ATAC mutations. We provide antenatal features and postnatal autopsy descriptions. This series shows the variable phenotypic pattern, even within cases occurring in the same family and affected by the same mutation. We also report two features for the first time in cases of MOPD type 1: hallux valgus and cerebral infundibular hamartoma.
From the first family, fetus 1 had IUGR (-2SD), severe skeletal anomalies (platyspondyly, brachydactyly and lack of ossification centres) and unilateral ventriculomegaly, without microcephaly (-1SD). Fetus 2 (sibling of fetus 1) had severe IUGR (-2.8SD) and severe microcephaly (-3.1SD) with few skeletal anomalies.
From the second family, fetus 3 had severe IUGR (-2.4SD), severe microcephaly (-3.5SD), hypoplastic corpus callosum and abnormal gyration. This fetus also demonstrated atypical features such as hallux valgus and a cerebral infundibular hamartoma. Fetus 4 (sibling of fetus 3) was diagnosed by antenatal molecular diagnosis and the pregnancy was surgically terminated at 17 weeks without contributive pathological examination.
In conclusion, mutations in the RNU4ATAC gene can be confirmed by antenatal molecular diagnosis. Our series shows that the phenotypic expression can be very heterogeneous even with the same mutation within the same family. Objectives: To evaluate the reliability of prenatal invasive and non-invasive diagnosis by a retrospective analysis on a single centre cohort of pregnancies with suspected toxoplasmosis from 1978 to 2015, mostly treated with a Spiramycin/Cotrimoxazole (Sp/C) protocol. Methods: We discussed prenatal diagnosis options with all women; 345 (32,4%) underwent amniocentesis, with the execution of inoculation tests in mice until 2006 and PCR since 1996. All women were offered monthly detailed ultrasound (US) to evaluate signs of Congenital Toxoplasmosis (CT), mainly ventriculomegaly, intracranial and/or liver calcifications. Results: Amniocentesis: out of 169 inoculation tests none was positive and all newborns were not infected. Out of 225 PCR, 16 (7,1%) were positive; 1 infant with negative PCR had CT diagnosed at birth -NPV: 99,4% (CI95%: 98,8-100%). Twelve infants with positive PCR didn't show any sign of infection at birth and at 1 year, 4 were lost to follow-up. US: in 549/636 (86,4%) cases all scans were normal; 23 (3,6%) had signs of CT and 64 (10%) had abnormalities not related with CT. CT was confirmed in 7 (30,4%) US positive and in 21 (3,4%) US negative fetuses. No fetuses with isolated bowel hyperechogenicity or increased placental thickness had CT. PPV for ventriculomegaly and/or intracranial/liver calcifications was 58% (CI95%: 44-72%). All US positive infected fetuses were symptomatic at birth whereas only 2 (9,5%) of US negative infected had symptoms. Conclusions: Relatively few women chose invasive diagnosis, possibly because in our Sp/C protocol prenatal diagnosis isn't decisional. A negative PCR offers a significant reassurance, but it's important to consider the possibility of late transmission. A positive PCR doesn't necessarily imply a poor prognosis in prenatally treated fetuses. US has less value in excluding transmission but can detect serious complications. The clinical significance of other abnormal US findings demands caution, even if maternal infection is confirmed. 
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